Calcinosis in systemic sclerosis.
Calcinosis in systemic sclerosis.
复制标题
DOI:
10.1097/bor.0000000000000896
复制
发表时间:
2022-11-01
影响因子:
5.1
通讯作者:
中科院分区:
文献类型:
--
作者:
To provide updated information on the prevalence, pathogenesis, diagnostics, and therapeutics of calcinosis cutis associated with systemic sclerosis (SSc). Observational studies show ethnic and geographical differences in the prevalence of calcinosis. In addition to clinical and serological associations, biochemical studies and in vivo models have attempted to explain theories behind its pathogenesis including prolonged state of inflammation, mechanical stress, hypoxia and dysregulation in bone and phosphate metabolism. Long-term use of proton pump inhibitors may increase the risk for calcinosis in SSc. Few single center observational studies have shown mild benefit with minocycline and topical sodium thiosulfate. Calcinosis cutis is the deposition of insoluble calcium in the skin and subcutaneous tissues. It affects up to 40% of SSc patients and causes significant morbidity. Long disease duration, features of vascular dysfunction, and osteoporosis have been associated with calcinosis. Altered levels of inorganic pyrophosphate and fibroblast growth factor-23 have been implicated in dysregulated phosphate metabolism that may lead to calcinosis in SSc. Plain radiography can help with diagnosis and quantifying the calcinosis burden. Surgical treatment remains the most effective therapy when feasible. At present, no medical therapies have proven efficacy in large randomized controlled trials.
影响因子:
2.5
作者:
Memida T;Matsuda S;Nakamoto T;Ouhara K;Kajiya M;Hirata S;Sugiyama E;Kakimoto N;Mizuno N
通讯作者:
Mizuno N